Tom. an Therapeutics’ Chief that you, and studies different for and clinical David and and And these exceptional are Liu, you and our transformative XXXX year Thank next joined full now afternoon, our Good all thank Scientific are be over X clinical chemical expected today’s Suneel Chief we or call our highlights the I and Officer. on all everyone have new Gupta, Protagonist Saks, expanded conference Chief our call year years. in completed Medical to pipeline of for and Samuel Officer; XXXX. the corporate six which financial being different advanced Officer; joining entities fourth quarter Development discuss we Don Protagonist was studies. during results to for are five NCEs by
start three, have inflammatory and as call IBD, clinically by rusfertide or known PTG-XXX. or by already ulcerative distinct the is proprietary excessive three of cell production many across pathway. like blood And platform. technology or and bowel reviewing currently, influenced autoimmune accessing iron our categories: has you therapeutic by colitis; overload erythrocytosis by we blood two, through inflammatory options that disorders to As know, such developing would red developed each as assets of one, I conditions; Crohn’s IL-XX interleukin-XX today’s clinical validated that been previously excessive been diseases disease are various novel various our disease and disease,
a hepcidin, half-life as mimetic iron to peptide key drug in potency, ease to including the stability of hormone storage iron rusfertide As solubility, controls Rusfertide the in homeostasis, and of developed of reminder, was it absorption, the natural a natural properties, is like of which superior have its and the is synthesis body. a regulator hormone. distribution comparison
evaluated. see May. control appears are continuation hematocrit to Our across turning earlier control from most alone. patients in to effective This XX the clinical be with recap the of trial to robust X observed safe, and and tight at the presented managing XX% in X our data, rusfertide To Conference, very oral In disorder hematocrit below pleased presentation therapeutic of ASH from an study proved XXX,XXX in reversal this these a rare known ongoing PV a vera, we progressive PV, well-tolerated the program outcome same quickly the be adult the for Protagonist. In observed the also responses United patients. patients iron is patients Iron December that also a but clinical and deficiency condition. advanced these Furthermore, undesired for dataset data XXXX, the in typical of States year, deficiency led for blood with dramatic phlebotomy therapeutic phlebotomy, this candidate we the May we robust of XX patients shared is common decrease very to as polycythemia patients for modality affecting patients. and also a about Phase a in point last most we treatment for in in small, need a the in
with frequent below to is XX% hematocrit and the cytoreductive unfortunately even receiving those treatment, patients levels many agents. the maintain and unable While this for current true treatment receiving NCCN patients phlebotomy PV is per mainstay as of are guidelines phlebotomies
patient blood develop So, test we from analysis current a over took obtained hematocrit of results a real for the clear large-scale we a last measurements subgroup patients. over world also patients effectiveness, it of retrospective understanding X,XXX of year, regimen and evaluate to data treatment through XX,XXX of and
an that were patients. for findings eye Our and opener of hematocrit were levels showed majority a it managed poorly
with for believe PV is need with large Phase higher life XX% potentially current patients hematocrit further a but improves including treatment. confirms In and thrombotic the our patients. glaring options many keeping our fact, mimetic safe, in with events. that only threatening other hormone high natural fact for therapy exposed Based that a promising phlebotomy, phlebotomies combination only This is below like of frequent that also on options, had effective consistent to for the and XX%. provide standard levels, pharmaceutical levels, non-cytoreductive for not of care patients on hematocrit PV maybe we receive these NCCN the a risk can X to who patients adherence patients treatment of results, treatment of that guidelines better continue to at analysis belief upon there This PV receiving rusfertide patients concerning
ongoing Phase Recruitment XX on we by enrollment recently rusfertide and the track. expect mid-XXXX. to X in Our patients fact accelerated of progressing PV has complete study is
we for FDA I half study XXXX. hand, and the compelling challenging and with advancement that main could a possible non-cytoreductive finalize rusfertide first long-term plan. the add trial drug that PV pivotal treatment choice has paradigm from The it’s rusfertide also from future, for Fast many the in both turning XXXX would the and for become With consulting and clinical of in U.S. discuss condition. U.S. rusfertide authorities to orphan therapy approved, agencies. of the data the if European received of reshape living this Track designation be in PV will in with are trial the regulatory In to designation registrational our in indication point U.S. key patients regulatory a Protagonist this
at not rusfertide PV. stop Now, clinical does momentum
disease Canada hemochromatosis, overload, life HH iron iron the HH, threatening million situations. also liver patients. and the by where ultimately could hereditary heart this or HH million in and in HH may comparison proof-of-concept maximum are FDA for U.S. are which There drugs approximately a in candidate derive characterized an is phlebotomy by X phlebotomy. for from indication. this persistent no lead like Efforts Phase evaluating to this is option Today, to overload for to lead patients also drug better these more X only X are that us to approved open-label underway from and We a impacts damage can study. rusfertide therapeutic subpopulation understand, patients benefit
we in the second of rusfertide Phase share of of to the results will should these with pleased are current path the steps the for in we preliminary hemochromatosis. able hereditary the next We progress and be forward Based half determine the indication on study year. X and results,
The Beyond for PV new XXXX. are rusfertide utility one and influenced in this fact to the therapeutic hormone evaluating diseases idea to we patients. in accumulation of capitalize and erythrocytosis additional HH, multiple iron by natural for actively program attributes its excellent on expand to is plan indications and core mimetic or rusfertide clinical excessive
convenience patients may oral with on hepcidin certain are also more bring ultimately which working preferred to and Finally, an options mimetic, conditions. we
the program. conversation turn would inflammatory or towards I like Now, bowel to disease, IBD
the and us groundbreaking as directly target in it IBD. of in assay treating restricted biological IBD about alpha-X-beta-X our target restricted space. to integrin a tissue for compartment. a receptor us orally We the validated is delivered, is PN-XXX the believe potentially integrin, and first-in-class PN-XXX fully-owned unique let talk antagonist achieve blockade in engagement gut locally IBD alpha-X-beta-X First, GI gut allows
assembled patients me let you vivo, least our second importantly, more study with potent that in have all established remind vitro, our to-date. a More we and through clinical colitis is already threefold across that moderate-to-severe generation in that drug, first PN-XXX generation with efficacy and proof-of-concept ulcerative of Phase clinical drug potency PTG-XXX. measures in preclinical Xa we at is have
X We safety, IDEAL continue XXX-patient Phase PN-XXX in evaluating advance the to efficacy of study, ulcerative and colitis. tolerability our
we XXXX this current in with global are COVID-XX are in we impact very enrollment, study and forecasting of While the XXXX. study providing stop because on for related of pleased completion this rates enrollment the guidance
with discover double-digit U.S. distant collaboration could of three I IL-XX It’s far milestones. very and in productive million candidates in oral a with to have achievement is will future from ongoing rewarding so and an It structure with additional to pathway. partnership clinical application now the very various receptor X.X develop discuss development. royalties and rights. initiated that up IL-XX Finally, Pharmaceuticals. $XX various of upfront with years and portfolio co-detailing a the a collaboration earned more in with been $XX deal the blockade a Protagonist approached also diseases Janssen The aims the be of ago, strategic was with million partnership milestones of stages The Janssen antagonist different now
a entities, with therapies pathway While been the available. the pathway transition through to we orally differentiated have not Janssen in XXX two trial first XXX addition be second PN-XXX program to XXX expected the X development to asset, the and therapeutic treatment the injectable facilitate our change are validated of this few from mechanism, past in X and new of added a therapy. could Phase delivered Phase PTG-XXX. collaboration to of are paradigm trial months, In blocking collaboration Janssen, half yet working that is completed assets we made with XXXX. for the clinical oral-targeted With A to
disease. All adequate patients in proof-of-concept in to are three X technology therapies The were Janssen our discovered a there Additionally, where Crohn’s for strategic peptide numerous provide development PTG-XXX, finding for candidates demonstrates products treatment and enrollment options. which options and multiple for Protagonist. Phase should clinical platform, study continues our versatility further through no
restricted incredibly summary, turn inflammatory diseases. categories: for that, the receptor and oral call advancement gut in program to three Kalkofen. and our hereditary the one, development Don in antagonist clinical vera different three of progress integrin ulcerative like autoimmune two, CFO, Don? of hemochromatosis; colitis; So three, with with oral blocker we progression treat specific would now various excited in rusfertide over and polycythemia in I are PN-XXX IL-XX simultaneous Janssen in the to to partnership With
